Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter registry study of ARNI impact on recombinant human brain natriuretic peptide efficacy in acute heart failure
ChiCTR2200065092Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of nesiritide in Acute Heart Failure (AHF) (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: NT-proBNP. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on ChiCTR2200065092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065092.